Abbott Laboratories Boosts FY25 Adj. EPS Outlook

Abbott Laboratories (ABT) raised its full-year 2025 adjusted earnings outlook to $5.10-$5.20 per share, up from its previous guidance, while projecting 7.5-8.0% organic sales growth. For the third quarter, the company anticipates adjusted earnings of $1.28-$1.32 per share, slightly below the $1.33 analyst consensus. Additionally, Abbott's board declared a quarterly dividend of $0.59 per share.

Analysis

Abbott Laboratories (ABT) has issued a mixed but incrementally positive update on its fiscal 2025 outlook. The company narrowed its full-year adjusted earnings per share guidance to a range of $5.10 to $5.20, from a previous range of $5.05 to $5.25. While this revision raises the lower bound, it also reduces the upper bound, keeping the midpoint effectively unchanged at $5.15, just below the current analyst consensus of $5.16. This is paired with a slightly more conservative organic sales growth forecast, now 7.5% to 8.0% versus a prior 7.5% to 8.5%. In the near term, the guidance for the third quarter projects adjusted EPS between $1.28 and $1.32, the midpoint of which is slightly below the Street's expectation of $1.33. Offsetting this near-term softness, the board's declaration of a $0.59 quarterly dividend reaffirms a commitment to consistent shareholder returns.

Key Decisions for Investors

• Consider the potential for near-term stock pressure stemming from the third-quarter earnings guidance miss, while weighing it against the stability implied by the narrowed full-year 2025 forecast.
• Evaluate positions in light of the updated guidance, as the current analyst consensus of $5.16 per share now sits at the high end of the company's projected range, potentially limiting the scope for future upward revisions.
• For income-oriented portfolios, the confirmed $0.59 quarterly dividend supports a hold strategy, reinforcing Abbott's role as a stable capital-return vehicle for long-term investors.